These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37080831)

  • 21. Malaria intervention scale-up in Africa: effectiveness predictions for health programme planning tools, based on dynamic transmission modelling.
    Korenromp E; Mahiané G; Hamilton M; Pretorius C; Cibulskis R; Lauer J; Smith TA; Briët OJ
    Malar J; 2016 Aug; 15(1):417. PubMed ID: 27538889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the safety, impact and effectiveness of RTS,S/AS01
    Praet N; Asante KP; Bozonnat MC; Akité EJ; Ansah PO; Baril L; Boahen O; Mendoza YG; Haine V; Kariuki S; Lamy M; Maleta K; Mungwira R; Ndeketa L; Oduro A; Ogutu B; Olewe F; Oneko M; Orsini M; Roman F; Bahmanyar ER; Rosillon D; Schuerman L; Sing'oei V; Terlouw DJ; Wéry S; Otieno W; Pirçon JY
    Malar J; 2022 Apr; 21(1):132. PubMed ID: 35468801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility, safety, and impact of the RTS,S/AS01
    Asante KP; Mathanga DP; Milligan P; Akech S; Oduro A; Mwapasa V; Moore KA; Kwambai TK; Hamel MJ; Gyan T; Westercamp N; Kapito-Tembo A; Njuguna P; Ansong D; Kariuki S; Mvalo T; Snell P; Schellenberg D; Welega P; Otieno L; Chimala A; Afari EA; Bejon P; Maleta K; Agbenyega T; Snow RW; Zulu M; Chinkhumba J; Samuels AM;
    Lancet; 2024 Apr; 403(10437):1660-1670. PubMed ID: 38583454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study.
    Camponovo F; Ockenhouse CF; Lee C; Penny MA
    BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insecticide-treated nets for preventing malaria.
    Pryce J; Richardson M; Lengeler C
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD000363. PubMed ID: 30398672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.
    Seo MK; Baker P; Ngo KN
    Malar J; 2014 Feb; 13():66. PubMed ID: 24564883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
    Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
    BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution.
    Diawara H; Walker P; Cairns M; Steinhardt LC; Diawara F; Kamate B; Duval L; Sicuri E; Sagara I; Sadou A; Mihigo J; Eckert E; Dicko A; Conteh L
    Malar J; 2021 Mar; 20(1):128. PubMed ID: 33663488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
    Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study.
    Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
    Malar J; 2015 Dec; 14():524. PubMed ID: 26702637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
    Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
    PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana.
    Darkwa S; de Wildt G; Dalaba M; Vidzro E; Ansah EK
    PLoS One; 2022; 17(6):e0268009. PubMed ID: 35675273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling population-level impact to inform target product profiles for childhood malaria vaccines.
    Hogan AB; Winskill P; Verity R; Griffin JT; Ghani AC
    BMC Med; 2018 Jul; 16(1):109. PubMed ID: 30001708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.
    Mandala WL; Harawa V; Dzinjalamala F; Tembo D
    Mol Biochem Parasitol; 2021 Nov; 246():111425. PubMed ID: 34666102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prioritizing the scale-up of interventions for malaria control and elimination.
    Winskill P; Walker PG; Cibulskis RE; Ghani AC
    Malar J; 2019 Apr; 18(1):122. PubMed ID: 30961603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
    Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
    BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden.
    Crowell V; Briët OJ; Hardy D; Chitnis N; Maire N; Di Pasquale A; Smith TA
    Malar J; 2013 Jan; 12():4. PubMed ID: 23286228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.